3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Recurrence
2
Prostatic Neoplasms
2
Small Cell Lung Carcinoma
1
Metastatic Castration-Resistant Prostate Cancer
1
Lymphoma, Follicular
1
Interventions
Prednisone
103
enzalutamide
76
Docetaxel
72
Abiraterone Acetate
68
Leuprolide
47
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
45
abiraterone
39
apalutamide
29
Prednisolone
27
bicalutamide
26
Zoledronic Acid
24
radium Ra 223 dichloride
22
pembrolizumab
22
darolutamide
22
Goserelin
22
Triptorelin Pamoate
17
cabazitaxel
16
Androgen Antagonists
15
sipuleucel-T
13
luprolide acetate gel depot
12
Injections
12
Dexamethasone
12
olaparib
11
gallium 68 PSMA-11
10
Mitoxantrone
10
Pluvicto
9
Ipilimumab
9
Dutasteride
9
Cyclophosphamide
9
relugolix
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Prostatic Neoplasms
×
PF06821497
×
Clear all
NCT07028853
2026-06-05
MEVPRO-3
Pfizer
Phase 3
Recruiting
1,000 enrolled
NCT06551324
2026-05-05
MEVPRO-1
Pfizer
Phase 3
Active not recruiting
600 enrolled